Drug intelligence / Profile preview

PeptiClere

Development stage: Discontinued
Lead developer: ProteoTech
Modality: Peptides
Administration: Intranasal

Overview

PeptiClere (also known as PTI-777) is a peptide-based therapeutic candidate developed by ProteoTech, Inc. for the treatment of Alzheimer's disease. Administered as a nasal spray, the drug is designed to target and inhibit the aggregation of amyloid-beta (Aβ) proteins into toxic fibrils and plaques, which are central to the pathogenesis of Alzheimer's. Additionally, PeptiClere is intended to promote the clearance of existing amyloid deposits in the brain. The intranasal delivery route is utilized to facilitate direct transport to the central nervous system, potentially improving efficacy and reducing systemic side effects. Development of the compound appears to have ceased following the inactivity of ProteoTech.

Brand names: PeptiClere

Targets

Aβ (Amyloid-beta peptides and aggregates)

Beyond the preview

Go deeper on PeptiClere.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PeptiClere.

Explore the full profile